Abbott (ABT) ended the recent trading session at $115.29, demonstrating a +2.74% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 1.04%. Meanwhile, the Dow lost 1.66%, and the Nasdaq, a tech-heavy index, lost 1.13%. Shares of the maker of infant formula, medical devices and drugs witnessed a gain of 4.46% over the previous month, beating the performance of the Medical sector with its gain of 0.7%, and the S&P 500's gain of 1.75%.Analysts and ...

NEENAH, WI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Plexus Corp. (NASDAQ: PLXS) announced today that it will attend the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on March 2, 2026. During the conference, Raymond James will host a fireside chat with Plexus’ management team at 10:25 a.m. Eastern Time. The fireside chat will be available via live webcast. What:Plexus Fireside Chat and Webcast at the Raymond James 47th Annual Institutional Investors Conference When:Monday March 2, 20 ...

Core Insights - Fabrinet published its Corporate Responsibility Report for the fiscal year ended June 27, 2025, highlighting progress in sustainable manufacturing, supply chain management, quality management, risk management, employee training, and community engagement [1][2]. Sustainable Manufacturing - The company achieved reduced electricity intensity and Scope 2 emissions intensity while lowering costs, natural resource consumption, and waste through 233 green stream mapping and reduce, reuse, recycle projects [5]. Quality Management - Continuous improvement initiatives were extended in 2025, including Kaizen & Lean Training, quarterly Kaizen and Six Sigma contests, weekly Gemba audits, and regular 5S audits to empower employees in contributing to high-quality and efficient operations [5]. Human Capital Management - Fabrinet was recognized by Thailand's Ministry of Labor for strong labor rights practices at both Pinehurst and Chonburi campuses in fiscal year 2025 [5]. Community Initiatives - The company received national recognition for its contributions to community development and youth empowerment [5].

Company Overview - Roper Technologies, Inc. (NASDAQ:ROP) has transitioned from a traditional industrial company to a software-centric firm over the past 15 years, acquiring various software companies and operating them independently [1][3]. Industry Focus - The company specializes in building software and technology products for sectors such as healthcare, education, and transportation, providing cloud-based management tools, data analytics, medical devices, and precision measurement systems [3]. Investment Perspective - Roper Technologies is recognized for its fascinating evolution and strong historical performance, with a legacy dating back to the late 1800s as a maker of home appliances and industrial products [1].

Core Insights - Gentex Corporation reported a consolidated net sales of $644.4 million for Q4 2025, a 19% increase from $541.6 million in Q4 2024, with VOXX contributing $103.4 million to this revenue [3][6] - The consolidated gross margin for Q4 2025 was 34.8%, up from 32.5% in Q4 2024, while the core Gentex gross margin was 35.5%, reflecting a 300 basis-point increase [4][6] - For the calendar year 2025, consolidated net sales reached $2.53 billion, a 10% increase from $2.31 billion in 2024, while core Gentex sales were $2.27 billion, a 2% decline compared to 2024 [12][16] Financial Performance - Consolidated income from operations for Q4 2025 was $120.1 million, compared to $89.8 million in Q4 2024, marking a significant increase [8] - The net income attributable to Gentex for Q4 2025 was $93.0 million, up from $87.7 million in Q4 2024, with earnings per diluted share increasing to $0.43 from $0.39 [11][6] - For the full year 2025, the consolidated net income attributable to Gentex was $384.8 million, down from $404.5 million in 2024, with earnings per diluted share at $1.74 compared to $1.76 in 2024 [16][17] Operational Highlights - Consolidated operating expenses in Q4 2025 were $104.4 million, up from $86.5 million in Q4 2024, primarily due to the VOXX acquisition [5] - Core Gentex operating expenses (excluding VOXX) were $79.8 million in Q4 2025, down from $86.5 million in Q4 2024, which included impairment charges [5][7] - The company repurchased 3.8 million shares in Q4 2025 at an average price of $23.43 per share, totaling $319.0 million for the year [21] Market and Product Insights - Gentex Automotive net sales for Q4 2025 were $527.6 million, slightly down from $531.3 million in Q4 2024, with a year-over-year decline in auto-dimming mirror shipments of 3% [18] - Other net sales, including products like dimmable aircraft windows and medical devices, increased to $13.3 million in Q4 2025 from $10.3 million in Q4 2024 [19] - VOXX's net sales contributed $267.2 million for the calendar year 2025, reflecting strong seasonal demand [20] Future Guidance - For 2026, the company expects consolidated revenue between $2.60 billion and $2.70 billion, with a gross margin target of 34% to 35% [24] - The company anticipates a slight decline in light vehicle production in its primary markets, with a forecasted total of 76.5 million units in 2026 [22][23] - The company aims to achieve approximately $40 million per year in positive cash flow from planned cost improvement initiatives [26]

Core Viewpoint - Baxter International Inc. will host a conference call to discuss its fourth-quarter 2025 financial results on February 12, 2026, at 7:30 a.m. Central Time [1] Group 1 - The conference call will be accessible via a pre-registration link and will also be webcasted on Baxter's website [1][2] - The call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting [2] Group 2 - Baxter is a leading global medtech company with a mission to provide essential healthcare solutions across various settings [3] - The company has approximately 38,000 team members dedicated to saving and sustaining lives through its portfolio of connected solutions and medical devices [3] - Baxter has been a trusted partner in healthcare for nearly a century, impacting millions of patients and healthcare providers [3]

Core Viewpoint - Abbott Laboratories (NYSE:ABT) is set to release its fiscal fourth-quarter earnings report, which may present opportunities for bullish options traders, despite the stock's recent underperformance [1][5]. Group 1: Company Overview - Abbott is recognized as a healthcare leader, providing financial stability and dividends, making it a suitable long-term investment for multi-year portfolio strategies [1]. - The demand for Abbott's products is largely non-discretionary, meaning that economic downturns do not significantly affect the need for its diagnostics equipment, medical devices, and nutritional products [3]. Group 2: Market Context - The stock has experienced a decline of over 2% at the start of the year and a 7% loss over the past six months, with a notable downturn beginning in mid-October [5]. - Despite the stock's weak performance, analysts remain optimistic about Abbott's future prospects, indicating a lack of short positions against the stock [6]. Group 3: Stock Analysis - Current analysis suggests that the stock is likely to range between $118 and $134 over the next 10 weeks, with a more focused range of $122 to $130 based on second-order analysis [12]. - The Black-Scholes model indicates a potential movement of about 6% up or down by the March 20 expiration date, while a second-order Markovian analysis suggests a narrower range of outcomes [14]. Group 4: Trading Strategy - A bullish trade strategy is recommended, specifically a 125/130 bull call spread expiring on March 20, with a maximum profit potential of 159% if the stock rises above the $130 strike price [20].

Group 1 - Plexus Corp. will release its fiscal first quarter 2026 results after market close on January 28, 2026 [1] - A conference call to discuss the results is scheduled for January 29, 2026, at 8:30 a.m. Eastern Time [2] - An audio webcast of the call will be available on the investor relations section of the Plexus website [1][2] Group 2 - Plexus Corp. specializes in designing, manufacturing, and servicing complex products in regulated environments [3] - The company operates in sectors such as Aerospace/Defense, Healthcare/Life Sciences, and Industrial [3] - Plexus has a global workforce of over 20,000 members across 26 facilities [3]

Group 1: U.S. Control Over Venezuelan Oil - The United States now controls every drop of oil coming out of Venezuela, with Russian tankers being intercepted off the Venezuelan coast [2] - Venezuela has initiated oil sales with a 30 million-barrel tranche, expected to increase to 50 million and then 100 million barrels, with proceeds managed by a White House-run fund [2] - The U.S. will dictate the terms of oil sales, with Venezuela required to purchase only American-made products, including agriculture and medical supplies [2] Group 2: Investment and Stability Concerns - Oil companies are concerned about the stability of the Venezuelan government as they consider new investments, with Chevron holding the largest stake and potentially increasing production from 50,000 to 200,000 barrels per day [3][4] - Overall production could rise to approximately 1 million barrels per day, up from around 800,000 barrels [4] - The transition to democracy in Venezuela must be "stable, proper and judicious," according to President Trump [3] Group 3: Broader Geopolitical Implications - The situation is viewed as a strategy to expel Russia and China from the Western Hemisphere and to undermine Cuba and Iran [5] - The focus on oil is seen as part of a larger narrative about promoting freedom and democracy in the region [5]

Group 1 - Venezuela will purchase only American-made products using revenue from its oil sales, including agricultural products, medicine, and medical devices [1] - The U.S. will receive 30 million to 50 million barrels of oil from Venezuela, which will be sold at market price [2] - The U.S. will control Venezuela's oil sales indefinitely to drive necessary changes in the country [3] Group 2 - The crude oil from Venezuela will be marketed starting with stored oil and will continue with future production [3] - The U.S. aims to leverage control over oil sales to implement changes in Venezuela [3]